Vardenafil (Levitra/Staxyn) Dosing in Renal Impairment

How Vardenafil Works and Why Kidney Function Matters

Vardenafil is a selective PDE5 inhibitor that blocks the breakdown of cyclic guanosine monophosphate (cGMP) in penile smooth muscle, allowing nitric oxide-mediated vasodilation to produce and sustain an erection. Kidney function affects how the body clears this drug and its active metabolite, M1, which carries roughly 28% of the parent compound's PDE5-inhibiting potency 1.

The liver handles the bulk of vardenafil metabolism through CYP3A4, with minor contributions from CYP3A5 and CYP2C isoforms 2. Renal excretion accounts for only 2 to 6% of an administered dose as unchanged drug. This hepatic-dominant clearance pattern explains why mild and moderate kidney disease has a relatively modest effect on drug exposure. A pharmacokinetic analysis submitted to the FDA demonstrated that patients with moderate renal impairment (CrCl 30 to 50 mL/min) showed a mean AUC increase of approximately 20 to 30% compared to subjects with normal kidney function 2. That increase falls within the range of normal inter-individual variability seen in healthy volunteers, which is why no dose change is required at this stage.

Severe renal impairment tells a different story. When CrCl drops below 30 mL/min, protein binding shifts, volume of distribution changes, and accumulation of the M1 metabolite becomes clinically relevant. The FDA label recommends initiating therapy at 5 mg in these patients, with cautious upward titration based on tolerability 2.

FDA-Labeled Dosing Recommendations by CKD Stage

The prescribing information for Levitra (vardenafil film-coated tablets) provides clear, staged guidance based on creatinine clearance. No renal-specific dose reduction is needed for CKD stages 1 through 3a. For patients with CrCl <30 mL/min (CKD stages 4 and 5), the recommended starting dose is 5 mg 2.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy and PDE5 inhibitors notes that "PDE5 inhibitors should be used with appropriate dose modifications in patients with significant renal or hepatic impairment" 3. This recommendation aligns with the FDA label but adds a practical point: clinicians should assess kidney function at baseline and periodically in men with risk factors for CKD progression, such as diabetes or hypertension.

The dose ceiling remains 20 mg for the film-coated tablet formulation, but reaching that ceiling from a 5 mg start requires careful titration. A reasonable approach is to try 5 mg on two or three separate occasions before considering a step up to 10 mg. The European Association of Urology (EAU) guidelines on male sexual dysfunction recommend evaluating efficacy and side effects across at least four to six attempts before concluding that a given dose has failed 4.

Staxyn, the orally disintegrating tablet (ODT) formulation, delivers 10 mg of vardenafil but has different bioavailability than the standard film-coated tablet. The ODT achieves approximately 21% higher Cmax than the 10 mg film-coated tablet when taken without water 2. Because the ODT was not studied in patients with severe renal impairment, the FDA label explicitly states that Staxyn should not be used in this population. There is no 5 mg ODT formulation available for dose reduction.

Pharmacokinetics in Kidney Disease: What the Data Show

The pharmacokinetic profile of vardenafil has been evaluated across the spectrum of renal function in dedicated studies submitted as part of the original NDA. Vardenafil is rapidly absorbed, reaching peak plasma concentrations in 30 to 120 minutes, with a terminal half-life of approximately 4 to 5 hours in healthy volunteers 2.

In subjects with mild renal impairment, the AUC of vardenafil was not significantly different from that of matched controls with normal renal function. Moderate impairment produced an AUC increase of 20 to 30%, as noted above. Protein binding remained stable at approximately 95% across mild and moderate CKD 2.

No dedicated pharmacokinetic study has been published for patients on hemodialysis. Given that vardenafil is 95% protein-bound and has a large volume of distribution, dialysis is unlikely to remove a clinically meaningful amount of drug. Nephrologists managing erectile dysfunction in dialysis patients generally follow the 5 mg starting dose used for severe CKD and titrate based on response and blood pressure stability 5.

A 2007 meta-analysis by Vecchio et al. examined PDE5 inhibitor use in CKD and dialysis populations and found that "PDE5 inhibitors are effective and generally well tolerated in men with chronic kidney disease, including those on dialysis" based on pooled data from 616 patients across nine trials 5. The analysis included studies of sildenafil, tadalafil, and vardenafil, and the overall adverse event profile was consistent with what is seen in general populations.

Vardenafil Versus Other PDE5 Inhibitors in Renal Impairment

Choosing among PDE5 inhibitors for a patient with CKD involves comparing pharmacokinetic behavior, dosing flexibility, and drug interaction profiles. All four FDA-approved PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) are primarily hepatically metabolized, but their renal dose adjustment thresholds differ.

Sildenafil's FDA label recommends a 25 mg starting dose when CrCl drops below 30 mL/min 6. Tadalafil requires no starting dose adjustment for mild or moderate renal impairment but recommends a 5 mg starting dose (maximum 10 mg, not more than once every 48 hours) for severe impairment with the on-demand regimen 7. Vardenafil's 5 mg threshold at CrCl <30 mL/min sits between these two approaches.

A practical advantage of vardenafil in CKD is its intermediate half-life. The 4 to 5 hour half-life means drug exposure resolves faster than tadalafil's 17.5-hour half-life, which may be preferable when managing patients with unstable blood pressure or fluctuating volume status around dialysis sessions 8. On the other hand, tadalafil's daily 2.5 or 5 mg regimen can simplify adherence for patients who prefer not to time doses around sexual activity.

Porst et al. demonstrated in a randomized, double-blind trial (N=452) that vardenafil at 10 mg and 20 mg significantly improved erectile function in men with diabetes mellitus, a population that frequently has concomitant renal disease 9. The mean IIEF-EF domain scores improved by 5.9 and 6.6 points for the 10 mg and 20 mg groups respectively, compared to 1.4 for placebo (P<0.001 for both comparisons). While this trial did not stratify by renal function, its inclusion of diabetic patients means a significant proportion likely had at least mild CKD.

Safety Considerations and Monitoring in CKD Patients

Blood pressure monitoring is the single most important safety measure when prescribing vardenafil to patients with renal impairment. CKD patients frequently take antihypertensives, and PDE5 inhibitors produce mild systemic vasodilation that can compound hypotensive effects. In healthy volunteers, vardenafil 20 mg reduced supine systolic blood pressure by a mean of 7 mmHg and diastolic by 8 mmHg 2.

The absolute contraindication with nitrates applies regardless of kidney function. This deserves special emphasis in CKD because angina and coronary artery disease are common comorbidities. Alpha-blockers, used frequently for benign prostatic hyperplasia in older men, also warrant caution. The FDA label recommends that vardenafil therapy be initiated only after patients are stable on alpha-blocker therapy, and that the starting dose of vardenafil should be 5 mg when co-administered with alpha-blockers 2.

QT prolongation is a known pharmacologic effect of vardenafil. A thorough QT study showed that vardenafil 10 mg prolonged QTc by a mean of 8 ms and the 80 mg supratherapeutic dose prolonged it by 10 ms 2. CKD patients often have electrolyte abnormalities (hypokalemia, hypomagnesemia, hypocalcemia) that independently increase QT prolongation risk. Checking a baseline ECG and recent electrolyte panel before prescribing is reasonable in CKD stage 4 or 5 patients.

The American Urological Association (AUA) 2018 guideline on erectile dysfunction states that "PDE5 inhibitors are first-line pharmacotherapy for ED" and recommends that "clinicians should discuss cardiovascular risk stratification before initiating ED treatment" 10. This recommendation has particular weight in CKD, where cardiovascular mortality is the leading cause of death.

Drug Interactions Relevant to Renal Patients

CKD patients take more medications on average than the general population, and several common CKD drugs interact with vardenafil. The most clinically significant interactions involve CYP3A4 inhibitors, which increase vardenafil plasma levels substantially.

Strong CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase vardenafil AUC by 300 to 1,000% depending on the inhibitor 2. The FDA label recommends a maximum vardenafil dose of 2.5 mg per 24 hours when co-administered with ketoconazole 200 mg, and a maximum of 2.5 mg per 72 hours with ketoconazole 400 mg or ritonavir 600 mg. These restrictions apply on top of any renal dose adjustments.

Moderate CYP3A4 inhibitors like erythromycin increase vardenafil AUC by approximately 300%, prompting a recommendation not to exceed 5 mg per 24 hours 2. Diltiazem and verapamil, calcium channel blockers used frequently in CKD for hypertension management, are moderate CYP3A4 inhibitors. A patient with CrCl <30 mL/min taking diltiazem would need to start at 5 mg (the renal adjustment) and be capped at 5 mg per 24 hours (the CYP3A4 interaction cap), making dose escalation impossible without switching the calcium channel blocker.

Grapefruit juice is a moderate CYP3A4 inhibitor that patients rarely disclose without being asked. Include it in medication reconciliation.

Phosphate binders, common in advanced CKD, do not have known interactions with vardenafil. Erythropoiesis-stimulating agents (ESAs) similarly lack documented PDE5 inhibitor interactions. Immunosuppressants in transplant recipients are a different matter: tacrolimus and cyclosporine are CYP3A4 substrates, and while they do not inhibit CYP3A4 at clinical doses, the shared metabolic pathway means clinicians should monitor for unexpected changes in levels of either drug.

Erectile Dysfunction Prevalence and Pathophysiology in CKD

Erectile dysfunction affects 50 to 80% of men on dialysis and 40 to 60% of men with CKD stages 3 to 5, compared to roughly 20 to 40% of age-matched men in the general population 11. The pathophysiology is multifactorial.

Uremic toxins impair endothelial nitric oxide synthase activity, directly reducing the substrate (cGMP) that PDE5 inhibitors are designed to protect. Autonomic neuropathy from uremia further blunts the neurogenic signals that initiate erections. Secondary hyperparathyroidism and anemia contribute through vascular calcification and reduced oxygen delivery, respectively. Hypogonadism is present in 40 to 60% of men with ESRD, and low testosterone independently predicts PDE5 inhibitor non-response 12.

This layered pathophysiology means that PDE5 inhibitor monotherapy may be insufficient in advanced CKD. A reasonable clinical sequence involves checking a morning total testosterone before initiating vardenafil. If testosterone is below 300 ng/dL, consider testosterone replacement in parallel with PDE5 inhibitor therapy, provided there are no contraindications such as polycythemia (hematocrit >54%) or untreated obstructive sleep apnea 3.

Practical Prescribing Protocol

For patients with CrCl >30 mL/min, start vardenafil at 10 mg taken 30 to 60 minutes before anticipated sexual activity on an empty stomach or after a low-fat meal. High-fat meals delay absorption by approximately 60 minutes and reduce Cmax by 18 to 50% 2.

For patients with CrCl <30 mL/min, start at 5 mg. Advise the patient to try the starting dose on at least four separate occasions before reporting treatment failure. If 5 mg is well tolerated but ineffective, increase to 10 mg. Document blood pressure at the prescribing visit and at follow-up after the first dose.

For dialysis patients, dose on non-dialysis days when possible. Blood pressure tends to be more stable 24 hours after a dialysis session, making this the optimal timing window.

Do not prescribe Staxyn (ODT) to any patient with CrCl <30 mL/min. If a patient strongly prefers the ODT formulation, confirm that their estimated GFR exceeds 30 mL/min/1.73 m² before prescribing.

Review the full medication list for CYP3A4 inhibitors and nitrates at every visit. Reassess renal function at least annually, as progression from moderate to severe CKD may trigger the need for dose reduction.

The minimum effective dose in a well-designed dose-finding study (Porst et al., 2003) was 5 mg, which produced statistically significant improvement over placebo on the IIEF-EF domain score 9. Starting at 5 mg in severe CKD is not a subtherapeutic concession. It is a dose proven to work.